A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients

被引:2
|
作者
Caliskan, Yasar [1 ,2 ]
Mirioglu, Safak [2 ,3 ]
Dirim, Ahmet Burak [2 ]
Ozluk, Yasemin [4 ]
Yegit, Ozan [2 ]
Aksoy, Elif [2 ]
Safak, Seda [2 ]
Guller, Nurana [2 ]
Demir, Erol [2 ]
Artan, Ayse Serra [2 ]
Oto, Ozgur Akin [2 ]
Besisik, Sevgi [5 ]
Yazici, Halil [2 ]
Turkmen, Aydin [2 ]
Lentine, Krista L. [1 ]
机构
[1] St Louis Univ, Sch Med, Ctr Abdominal Transplantat, 3660 Vista Ave, St Louis, MO 63110 USA
[2] Istanbul Univ, Istanbul Sch Med, Div Nephrol, Istanbul, Turkey
[3] Bezmialem Vakif Univ, Div Nephrol, Sch Med, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Sch Med, Dept Pathol, Istanbul, Turkey
[5] Istanbul Univ, Istanbul Sch Med, Div Hematol, Istanbul, Turkey
关键词
antibody mediated rejection; kidney transplantation; plasmapheresis; rejection; HUMORAL REJECTION; ALLOGRAFT-REJECTION; PLASMA-EXCHANGE; RITUXIMAB; IMMUNOADSORPTION; OUTCOMES; THERAPY; RESCUE;
D O I
10.1111/1744-9987.13937
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Results Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m(2) [95% CI]; 0.96 [0.94-0.99]), rituximab use (HR [95% CI]; 0.42 [0.21-0.84]), interstitial inflammation (i) (HR [95% CI]; 2.05 [1.13-3.69]), and transplant glomerulopathy (cg) (HR [95% CI]; 1.46 [1.13-1.87]) were associated with graft loss. Conclusion These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 50 条
  • [21] Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Boonpheng, Boonphiphop
    De Castro, Iris Camille C.
    Ng, Yue-Harn
    Blosser, Christopher
    Bakthavatsalam, Ramasamy
    Gimferrer, Idoia
    Smith, Kelly
    Leca, Nicolae
    CLINICAL TRANSPLANTATION, 2023, 37 (05)
  • [22] Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients
    Halloran, Philip F.
    Chang, Jessica
    Famulski, Konrad
    Hidalgo, Luis G.
    Salazar, Israel D. R.
    Lopez, Maribel Merino
    Matas, Arthur
    Picton, Michael
    de Freitas, Declan
    Bromberg, Jonathan
    Seron, Daniel
    Sellares, Joana
    Einecke, Gunilla
    Reeve, Jeff
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (07): : 1711 - 1720
  • [23] Outcome of Renal Transplant Recipients With Chronic Antibody Mediated Rejection - The Role of Intravenous Immunoglobulin and Plasmapheresis Treatment.
    Ma, M.
    Lam, M.
    Choy, C.
    Chan, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 511 - 511
  • [24] Outcome of Renal Transplant Recipients With Chronic Antibody Mediated Rejection - The Role of Intravenous Immunoglobulin and Plasmapheresis Treatment.
    Ma, M.
    Lam, M.
    Choy, C.
    Chan, T.
    TRANSPLANTATION, 2014, 98 : 511 - 511
  • [25] Retrospective Analysis of Kidney Transplant Recipients with Antibody-Mediated Rejection
    Pineiro, G.
    Desousa, E.
    Villarreal, J.
    Lozano, M.
    Cid, J.
    Sole, M.
    Oppenheimer, F.
    Diekmann, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 536 - 536
  • [26] The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients-A Systematic Review
    Roberts, Darren M.
    Jiang, Simon H.
    Chadban, Steven J.
    TRANSPLANTATION, 2012, 94 (08) : 775 - 783
  • [27] Eculizumab for the Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients: A Single Center Experience.
    Chi, A.
    Phillips, J.
    Quan, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 509 - 509
  • [28] Lung Transplant Recipients Suspected of Antibody Mediated Rejection Treated with Plasmapheresis Have a Poor Prognosis
    Dirks, C. G.
    Damholt, M. B.
    Szpirt, W.
    Bruunsgaard, H.
    Andersen, C. B.
    Carlsen, J.
    Perch, M.
    Mared, L.
    Iversen, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S264 - S264
  • [29] Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients
    Ahmadi, F.
    Dashti-Khavidaki, S.
    Khatami, M. R.
    Gatmir, M.
    Mahdavi-Mazdeh, M.
    Najafi, M. T.
    Foroozanfar, Z.
    Mahdizadeh, A.
    Derafshi, S.
    INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 2019, 10 (03): : 127 - 136
  • [30] Tocilizumab for treatment of antibody mediated rejection in kidney transplant patients
    Szabo, Eszter
    Marton, Adrienn
    Remport, Adam
    Torok, Szilard
    Patonai, Attila
    Piros, Laszlo
    Fintha, Attila
    Szijarto, Attila
    Wagner, Laszlo
    Cseprekal, Orsolya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39